Adicet Bio Inc (ACET) Stock Analysis
Verdict: AVOID
Pre-revenue clinical risk and heavy cash burn outweigh Phase 1 prula-cel upside, making recent severe price declines a critical warning.
Investment score: 35/100
Analysis as of
Is Adicet Bio Inc stock worth reviewing? AI model thesis
The AI model perspective rates ACET as an AVOID. Pre-revenue status, severe technical breakdown (-27.5% in one session to $6.54 USD), and an annual cash burn of ~$84M USD outweigh Phase 1 pipeline potential.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 40/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Adicet Bio Inc opportunities and risks
What speaks for ACET
- Phase 1 prula-cel efficacy data in autoimmune indications
What speaks against ACET
- Severe cash runway depletion and dilution threat
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ACET | n/a | 0.0x | n/a | 0.0% | 0.0% | -139.7% |
| TENX | n/a | 0.0x | 1.0x | 0.0% | 0.0% | -93.3% |
| RNXT | n/a | 35.7x | n/a | 84.4% | -621.7% | -16.9% |
| XBIT | n/a | 0.0x | 1.0x | 0.0% | 0.0% | -61.9% |
| CNTB | n/a | 22.7x | n/a | 100.0% | -1763.4% | -47.8% |
| FRMM | n/a | 6.0x | n/a | 82.3% | -4896.8% | -114.0% |
| Peer median | n/a | 6.0x | n/a | 82.3% | -621.7% | -61.9% |
Frequently asked questions about Adicet Bio Inc (ACET)
Is ACET stock a good investment?
The cached TradeMates AI model rates Adicet Bio Inc as AVOID with an investment score of 35/100. The AI model perspective rates ACET as an AVOID. Pre-revenue status, severe technical breakdown (-27.5% in one session to $6.54 USD), and an annual cash burn of ~$84M USD outweigh Phase 1 pipeline potential. This is algorithmic model output, not personal investment advice.
Is ACET stock a buy?
The TradeMates model verdict for ACET is AVOID with an investment score of 35/100. Treat this as a model signal to review, not a personal buy recommendation.